Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 43

1.

A Comparison of Three Methods for the Detection of Circulating Tumor Cells in Patients with Early and Metastatic Breast Cancer.

Politaki E, Agelaki S, Apostolaki S, Hatzidaki D, Strati A, Koinis F, Perraki M, Saloustrou G, Stoupis G, Kallergi G, Spiliotaki M, Skaltsi T, Lianidou E, Georgoulias V, Mavroudis D.

Cell Physiol Biochem. 2017;44(2):594-606. doi: 10.1159/000485115. Epub 2017 Nov 20.

2.

Prognostic value of chemotherapy-resistant CK19mRNA-positive circulating tumor cells in patients with advanced/metastatic non-small cell lung cancer.

Milaki G, Messaritakis I, Koinis F, Kotsakis A, Apostolaki S, Dermitzaki EK, Perraki M, Hatzidaki D, Georgoulias V.

Cancer Chemother Pharmacol. 2017 Jul;80(1):101-108. doi: 10.1007/s00280-017-3339-0. Epub 2017 May 18.

PMID:
28523597
3.

Effect of front-line chemotherapy on circulating CK-19 mRNA-positive cells in patients with metastatic breast cancer.

Georgoulias V, Apostolaki S, Bozionelou V, Politaki E, Perraki M, Georgoulia N, Kalbakis K, Kotsakis A, Xyrafas A, Agelaki S, Mavroudis D.

Cancer Chemother Pharmacol. 2014 Dec;74(6):1217-25. doi: 10.1007/s00280-014-2598-2. Epub 2014 Oct 26.

PMID:
25344760
4.

Detection of circulating cytokeratin-19 mRNA-positive cells in the blood and the mitotic index of the primary tumor have independent prognostic value in early breast cancer.

Tryfonidis K, Kafousi M, Perraki M, Apostolaki S, Agelaki S, Georgoulias V, Stathopoulos E, Mavroudis D.

Clin Breast Cancer. 2014 Dec;14(6):442-50. doi: 10.1016/j.clbc.2014.04.001. Epub 2014 Jun 2.

PMID:
24958324
5.

Differential effect of adjuvant taxane-based and taxane-free chemotherapy regimens on the CK-19 mRNA-positive circulating tumour cells in patients with early breast cancer.

Xenidis N, Perraki M, Apostolaki S, Agelaki S, Kalbakis K, Vardakis N, Kalykaki A, Xyrafas A, Kakolyris S, Mavroudis D, Georgoulias V.

Br J Cancer. 2013 Feb 19;108(3):549-56. doi: 10.1038/bjc.2012.597. Epub 2013 Jan 17.

6.

Clinical relevance of circulating CK-19mRNA-positive tumour cells before front-line treatment in patients with metastatic breast cancer.

Androulakis N, Agelaki S, Perraki M, Apostolaki S, Bozionelou V, Pallis A, Kalbakis K, Xyrafas A, Mavroudis D, Georgoulias V.

Br J Cancer. 2012 Jun 5;106(12):1917-25. doi: 10.1038/bjc.2012.202.

7.

Trastuzumab decreases the incidence of clinical relapses in patients with early breast cancer presenting chemotherapy-resistant CK-19mRNA-positive circulating tumor cells: results of a randomized phase II study.

Georgoulias V, Bozionelou V, Agelaki S, Perraki M, Apostolaki S, Kallergi G, Kalbakis K, Xyrafas A, Mavroudis D.

Ann Oncol. 2012 Jul;23(7):1744-50. doi: 10.1093/annonc/mds020. Epub 2012 Feb 29.

PMID:
22377561
8.

Synthesis of TiO2 nano-powders prepared from purified sulphate leach liquor of red mud.

Tsakiridis PE, Oustadakis P, Katsiapi A, Perraki M, Agatzini-Leonardou S.

J Hazard Mater. 2011 Oct 30;194:42-7. doi: 10.1016/j.jhazmat.2011.07.072. Epub 2011 Aug 5.

PMID:
21868153
9.

Cytokeratin-19 mRNA-positive circulating tumor cells during follow-up of patients with operable breast cancer: prognostic relevance for late relapse.

Saloustros E, Perraki M, Apostolaki S, Kallergi G, Xyrafas A, Kalbakis K, Agelaki S, Kalykaki A, Georgoulias V, Mavroudis D.

Breast Cancer Res. 2011 Jun 10;13(3):R60. doi: 10.1186/bcr2897.

10.

Brown diamonds from an eclogite xenolith from Udachnaya kimberlite, Yakutia, Russia.

Stepanov AS, Korsakov AV, Yuryeva OP, Nadolinniy VA, Perraki M, De Gussem K, Vandenabeele P.

Spectrochim Acta A Mol Biomol Spectrosc. 2011 Oct;80(1):41-8. doi: 10.1016/j.saa.2011.01.006. Epub 2011 Jan 13.

PMID:
21324732
11.

First findings of monocrystalline aragonite inclusions in garnet from diamond-grade UHPM rocks (Kokchetav Massif, Northern Kazakhstan).

Korsakov AV, Vandenabeele P, Perraki M, Moens L.

Spectrochim Acta A Mol Biomol Spectrosc. 2011 Oct;80(1):21-6. doi: 10.1016/j.saa.2010.12.024. Epub 2010 Dec 21.

PMID:
21247793
12.

Prognostic significance of the detection of peripheral blood CEACAM5mRNA-positive cells by real-time polymerase chain reaction in operable colorectal cancer.

Vardakis N, Messaritakis I, Papadaki C, Agoglossakis G, Sfakianaki M, Saridaki Z, Apostolaki S, Koutroubakis I, Perraki M, Hatzidaki D, Mavroudis D, Georgoulias V, Souglakos J.

Clin Cancer Res. 2011 Jan 1;17(1):165-73. doi: 10.1158/1078-0432.CCR-10-0565. Epub 2010 Nov 11.

13.

Detection of cytokeratin-19 mRNA-positive cells in the peripheral blood and bone marrow of patients with operable breast cancer.

Daskalaki A, Agelaki S, Perraki M, Apostolaki S, Xenidis N, Stathopoulos E, Kontopodis E, Hatzidaki D, Mavroudis D, Georgoulias V.

Br J Cancer. 2009 Aug 18;101(4):589-97. doi: 10.1038/sj.bjc.6605183. Epub 2009 Jul 21.

14.

Cytokeratin-19 mRNA-positive circulating tumor cells after adjuvant chemotherapy in patients with early breast cancer.

Xenidis N, Ignatiadis M, Apostolaki S, Perraki M, Kalbakis K, Agelaki S, Stathopoulos EN, Chlouverakis G, Lianidou E, Kakolyris S, Georgoulias V, Mavroudis D.

J Clin Oncol. 2009 May 1;27(13):2177-84. doi: 10.1200/JCO.2008.18.0497. Epub 2009 Mar 30.

PMID:
19332733
15.

Single and multiphase inclusions in metapelitic garnets of the Rhodope Metamorphic Province, NE Greece.

Mposkos E, Perraki M, Palikari S.

Spectrochim Acta A Mol Biomol Spectrosc. 2009 Aug;73(3):477-83. doi: 10.1016/j.saa.2008.12.035. Epub 2008 Dec 30.

PMID:
19181569
16.

Detection of occult HER2 mRNA-positive tumor cells in the peripheral blood of patients with operable breast cancer: evaluation of their prognostic relevance.

Apostolaki S, Perraki M, Kallergi G, Kafousi M, Papadopoulos S, Kotsakis A, Pallis A, Xenidis N, Kalmanti L, Kalbakis K, Agelaki S, Kalykaki A, Stournaras C, Stathopoulos E, Georgoulias V, Mavroudis D.

Breast Cancer Res Treat. 2009 Oct;117(3):525-34. doi: 10.1007/s10549-008-0239-3. Epub 2008 Nov 19. Erratum in: Breast Cancer Res Treat. 2009 Oct;117(3):539.

PMID:
19016323
17.

Prognostic value of the molecular detection of circulating tumor cells using a multimarker reverse transcription-PCR assay for cytokeratin 19, mammaglobin A, and HER2 in early breast cancer.

Ignatiadis M, Kallergi G, Ntoulia M, Perraki M, Apostolaki S, Kafousi M, Chlouverakis G, Stathopoulos E, Lianidou E, Georgoulias V, Mavroudis D.

Clin Cancer Res. 2008 May 1;14(9):2593-600. doi: 10.1158/1078-0432.CCR-07-4758.

18.

Molecular detection and prognostic value of circulating cytokeratin-19 messenger RNA-positive and HER2 messenger RNA-positive cells in the peripheral blood of women with early-stage breast cancer.

Ignatiadis M, Perraki M, Apostolaki S, Politaki E, Xenidis N, Kafousi M, Stathopoulos E, Lianidou E, Sotiriou C, Georgoulias V, Mavroudis D.

Clin Breast Cancer. 2007 Dec;7(11):883-9. doi: 10.3816/CBC.2007.n.054.

PMID:
18269779
19.

Different prognostic value of cytokeratin-19 mRNA positive circulating tumor cells according to estrogen receptor and HER2 status in early-stage breast cancer.

Ignatiadis M, Xenidis N, Perraki M, Apostolaki S, Politaki E, Kafousi M, Stathopoulos EN, Stathopoulou A, Lianidou E, Chlouverakis G, Sotiriou C, Georgoulias V, Mavroudis D.

J Clin Oncol. 2007 Nov 20;25(33):5194-202. Epub 2007 Oct 22.

PMID:
17954712
20.

The luminescent carbon-bearing microinclusion enigma in the Kimi Unit, Rhodope, Greece: Raman microscopic point analyses and mapping with different lasers.

Perraki M, Smith DC, Mposkos E.

Spectrochim Acta A Mol Biomol Spectrosc. 2007 Dec 15;68(4):1077-84. Epub 2007 Aug 11.

PMID:
17851123

Supplemental Content

Loading ...
Support Center